Page last updated: 2024-10-29

ketorolac and Pseudophakia

ketorolac has been researched along with Pseudophakia in 5 studies

Ketorolac: A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is an NSAID and is used principally for its analgesic activity. (From Martindale The Extra Pharmacopoeia, 31st ed)
ketorolac : A racemate comprising equimolar amounts of (R)-(+)- and (S)-(-)-5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid. While only the (S)-(-) enantiomer is a COX1 and COX2 inhibitor, the (R)-(+) enantiomer exhibits potent analgesic activity. A non-steroidal anti-inflammatory drug, ketorolac is mainly used (generally as the tromethamine salt) for its potent analgesic properties in the short-term management of post-operative pain, and in eye drops to relieve the ocular itching associated with seasonal allergic conjunctivitis. It was withdrawn from the market in many countries in 1993 following association with haemorrhage and renal failure.
5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid : A member of the class of pyrrolizines that is 2,3-dihydro-1H-pyrrolizine which is substituted at positions 1 and 5 by carboxy and benzoyl groups, respectively.

Pseudophakia: Presence of an intraocular lens after cataract extraction.

Research Excerpts

ExcerptRelevanceReference
"To evaluate whether ketorolac ophthalmic drops prescribed four times a day can be associated with improved visual acuity and prompt resolution of edema for patients with pseudophakic cystoid macular edema identified more than 24 months after cataract surgery."9.09Ketorolac treatment of pseudophakic cystoid macular edema identified more than 24 months after cataract extraction. ( Bressler, NM; Bressler, SB; Schachat, AP; Weisz, JM, 1999)
"To assess the effectiveness of ketorolac vs control for prevention of acute pseudophakic cystoid macular edema (CME)."8.88Ketorolac therapy for the prevention of acute pseudophakic cystoid macular edema: a systematic review. ( Cordero-Coma, M; Gallagher, MJ; Yilmaz, T, 2012)
"Although NSAID therapy seems to potentiate the improvements produced by corticosteroids and antivascular endothelial growth factor therapy for chronic pseudophakic cystoid macular edema, only nepafenac- and bromfenac-treated eyes showed reduced retinal thickness at 12 weeks and 16 weeks."5.14NSAIDs in combination therapy for the treatment of chronic pseudophakic cystoid macular edema. ( Bahrani, H; Fox, JE; Warren, KA, 2010)
"To evaluate whether ketorolac ophthalmic drops prescribed four times a day can be associated with improved visual acuity and prompt resolution of edema for patients with pseudophakic cystoid macular edema identified more than 24 months after cataract surgery."5.09Ketorolac treatment of pseudophakic cystoid macular edema identified more than 24 months after cataract extraction. ( Bressler, NM; Bressler, SB; Schachat, AP; Weisz, JM, 1999)
"To assess the effectiveness of ketorolac vs control for prevention of acute pseudophakic cystoid macular edema (CME)."4.88Ketorolac therapy for the prevention of acute pseudophakic cystoid macular edema: a systematic review. ( Cordero-Coma, M; Gallagher, MJ; Yilmaz, T, 2012)
"To determine the rate of postoperative cystoid macular edema (CME) in patients undergoing cataract surgery treated with intraoperative intracameral and postoperative topical nonsteroidal antiinflammatory drugs (NSAIDs) without steroids."1.56Rate of pseudophakic cystoid macular edema using intraoperative and topical nonsteroidal antiinflammatory drugs alone without steroids. ( Hess, J; Kauffman, L; Walter, K, 2020)

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (20.00)18.2507
2000's0 (0.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80

Authors

AuthorsStudies
Walter, K1
Kauffman, L1
Hess, J1
Grzybowski, A1
Adamiec-Mroczek, J1
Warren, KA1
Bahrani, H1
Fox, JE1
Yilmaz, T1
Cordero-Coma, M1
Gallagher, MJ1
Weisz, JM1
Bressler, NM1
Bressler, SB1
Schachat, AP1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Effect of Preoperative Topical Ketorolac 0.45% on Aqueous Cytokine Levels and Macular Thickness in Diabetic and Non Diabetic Patients Undergoing Cataract Surgery[NCT02646072]Phase 480 participants (Actual)Interventional2014-08-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

1 review available for ketorolac and Pseudophakia

ArticleYear
Ketorolac therapy for the prevention of acute pseudophakic cystoid macular edema: a systematic review.
    Eye (London, England), 2012, Volume: 26, Issue:2

    Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Cataract Extraction; Humans; Ketorolac; Macu

2012

Trials

2 trials available for ketorolac and Pseudophakia

ArticleYear
NSAIDs in combination therapy for the treatment of chronic pseudophakic cystoid macular edema.
    Retina (Philadelphia, Pa.), 2010, Volume: 30, Issue:2

    Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Antibodie

2010
Ketorolac treatment of pseudophakic cystoid macular edema identified more than 24 months after cataract extraction.
    Ophthalmology, 1999, Volume: 106, Issue:9

    Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cataract Extraction; Chronic Disea

1999

Other Studies

2 other studies available for ketorolac and Pseudophakia

ArticleYear
Rate of pseudophakic cystoid macular edema using intraoperative and topical nonsteroidal antiinflammatory drugs alone without steroids.
    Journal of cataract and refractive surgery, 2020, Volume: 46, Issue:3

    Topics: Administration, Ophthalmic; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal;

2020
Topical Nonsteroidal Anti-inflammatory Drugs for Cystoid Macular Edema Prevention in Patients With Diabetic Retinopathy.
    American journal of ophthalmology, 2017, Volume: 181

    Topics: Administration, Ophthalmic; Anti-Inflammatory Agents, Non-Steroidal; Diabetic Retinopathy; Humans; K

2017